China Supply Antineoplastic API CAS 119413-54-6 Topotecan Hydrochloride

Model NO.: 119413-54-6
CAS: 119413-54-6
Appearance: White Powders
Package: 100g/1kg/Foil Bag
Trademark: WHSO
Transport Package: Foiled Bag, Perfect Discreet, as Required
Specification: 1kg/foil bag
Origin: China
HS Code: 2937290090
Model NO.: 119413-54-6
CAS: 119413-54-6
Appearance: White Powders
Package: 100g/1kg/Foil Bag
Trademark: WHSO
Transport Package: Foiled Bag, Perfect Discreet, as Required
Specification: 1kg/foil bag
Origin: China
HS Code: 2937290090
Antineoplastic Pharmaceutical Raw Materials Topotecan Hydrochloride CAS 119413-54-6 


China Recommend Steroid Powders/Injection Steroid liquid/Peptides/Sarms/Local anesthetics/Nootropics/Antidepressant/Health Care Supplement......


Quick Details for Topotecan hydrochloride

Product Name: Topotecan hydrochloride 
Synonyms: TOPOTECAN MONOHYDROCHLORIDE;TOPOTECAN HCL;SKF-104864A;9-[(DIMETHYLAMINO)METHYL]-10-HYDROXY-(20S)-CAMPTOTHECIN, HCL;(4S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4',6-7]INDOLIZINO[1,2-B]QUINOLINE-3,14(4H,12H)-DIONE;HYDROCHLORIDE;topetecan hydrochloride;5-PIPERAZIN-1-YL-BENZOFURAN-2-CARBOXYLIC ACID ETHYL ESTER 
CAS: 119413-54-6 
MF: C23H24ClN3O5 
MW: 457.91 
Product Categories: straight chain compounds;Active Pharmaceutical Ingredients;Antineoplastic;Amino Acids 13C, 2H, 15N;Amino Acids & Derivatives;Intermediates & Fine Chemicals;Isotope Labeled Compounds;Pharmaceuticals;Chiral Reagents;Inhibitors;Isotope Labelled Compounds;Anti-cancer & immunity;API 
Melting point : 213-218°C 
Storage temp. : Refrigerator
Chemical Properties : White Crystalline Solid 
Usage : Naturally occurring amino acid; precursor of tetrapyrroles in the biosynthesis of chlorophyll and heme. Antineoplastic (photosensitizer) 
Usage : antineoplastic; topoisomerase I inhibitor 
Usage : A DNA topoisomerase I inhibitor; semisynthetic analog of Camptothecin. Antineoplastic. Topotecan hydrochloride is a chemotherapy agent that is a topoisomerase 1 inhibitor. 


Anticancer drug 

Topotecan hydrochloride is a water-soluble derivative of camptothecin, which is the form of hydrochloride of topotecan. It is successfully developed by the SmithKline Beecham US company, and approved by the FDA in the United States in 1996. Its trade name is Hycamtin. It is applied in the treatment of ovarian cancer (OVC) as the second-line therapy. 

In 1999 the US Food and Drug Administration (FDA) has approved topotecan hydrochloride as small cell lung cancer (SCLC) therapeutic drug. It has been available in the UK, Germany, France and other dozens of countries and regions. The 3 clinical trials are ongoing for this medicine which is used to treat non-small cell lung cancer, cervical cancer, myelodysplastic syndrome. 

Topotecan hydrochloride can enter the blood brain barrier. It has the same effect of oral and intravenous injection. The drug has low toxicity predictable bone marrow suppression, and other minor non-hematologic toxicity. Currently there are manufacturers, for clinical treatment of small cell lung cancer, ovarian cancer and other tumors.

Topotecan hydrochloride inhibits the activity of topoisomerase I, which is required for DNA replication. After intravenous injection, the product is hydrolyzed in the blood, and excreted by urinary. This product has a rapid serum clearance rate, which is 62L/h. It is widely distributed in vivo, and Its half-lifetime is about 2~3h. Preclinical trials have shown that the product has anti-tumor activity on all kinds of types of tumor. In I clinical trial, to patients with ovarian cancer that is cisplatin tolerance, this product also has significant anti-tumor effect. 


Topotecan hydrochloride Clinical studies 

In a open randomized trial, 226 cases who used cisplatin or carboplatin invalid or recurrent advanced ovarian cancer women changed to this product, and compared with paclitaxel. In 112 patients who used topotecan hydrochloride, 22 cases were effective, so the effective rate was 20%. In 114 patients treated with paclitaxel, 14 cases were effective, so the effective rate was 12%. Used this product for treatment which has made significant improvement in the average time of 23 weeks, while 14 weeks for paclitaxel. In a non-controlled trial to 111 women patients with refractory advanced ovarian cancer, 16 cases were preferabe after treatment, occupied with 14%, and the curative effect average time was 16-week, and the average survival time was 52-week. In an open trial, 67 cases were ineffective treated with cisplatin and paclitaxel for advanced ovarian cancer. However, 9 cases who changed to this product were effective, and the effective rate was 13%. 


Topotecan hydrochloride Side effects 

It can appear toxicity of bone marrow suppression in limited doses, especially it can cause neutropenia. It often induced thrombocytopenia and anemia. Sometimes red blood cell and platelet transfusion is necessary. It can also be nausea, vomiting, hair loss, diarrhea, abdominal pain, gastritis and weakness, but all of them were mild.  


Topotecan hydrochloride Uses 

It is used as antineoplastic agent. 


 
More products you may like

Sulbutiamine CAS 3286-46-2
Aniracetam CAS 72432-10-1
Noopept CAS 157115-85-0
Idra-21 CAS 22503-72-6
NSI-189 Free Base CAS 1270138-40-3
NSI-189 Phosphate CAS 1270138-41-4
9-fluorenol CAS 1689-64-1
Coluracetam CAS 135463-81-9
Sunifiram CAS 314728-85-3
Pramiracetam CAS 68497-62-1
4-Aminobutyric acid CAS 56-12-2
Piracetam CAS 7491-74-9
Oxiracetam CAS 62613-82-5
Fasoracetam CAS 110958-19-5
Nefiracetam CAS 77191-36-7
Centrophenoxine CAS 3685-84-5
Pikamilon Sodium CAS 62936-56-5
PRL-8-53 HCL CAS : 51352-87-5
Meclofenoxate hydrochloride CAS : 3685-84-5
Levodopa(L-DOPA) CAS : 59-92-7
Etiracetam(UCB-6474) CAS : 33996-58-6
Antineoplastic Pharmaceutical Raw Materials Topotecan Hydrochloride CAS 119413-54-6 


China Recommend Steroid Powders/Injection Steroid liquid/Peptides/Sarms/Local anesthetics/Nootropics/Antidepressant/Health Care Supplement......


Quick Details for Topotecan hydrochloride

Product Name: Topotecan hydrochloride 
Synonyms: TOPOTECAN MONOHYDROCHLORIDE;TOPOTECAN HCL;SKF-104864A;9-[(DIMETHYLAMINO)METHYL]-10-HYDROXY-(20S)-CAMPTOTHECIN, HCL;(4S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4',6-7]INDOLIZINO[1,2-B]QUINOLINE-3,14(4H,12H)-DIONE;HYDROCHLORIDE;topetecan hydrochloride;5-PIPERAZIN-1-YL-BENZOFURAN-2-CARBOXYLIC ACID ETHYL ESTER 
CAS: 119413-54-6 
MF: C23H24ClN3O5 
MW: 457.91 
Product Categories: straight chain compounds;Active Pharmaceutical Ingredients;Antineoplastic;Amino Acids 13C, 2H, 15N;Amino Acids & Derivatives;Intermediates & Fine Chemicals;Isotope Labeled Compounds;Pharmaceuticals;Chiral Reagents;Inhibitors;Isotope Labelled Compounds;Anti-cancer & immunity;API 
Melting point : 213-218°C 
Storage temp. : Refrigerator
Chemical Properties : White Crystalline Solid 
Usage : Naturally occurring amino acid; precursor of tetrapyrroles in the biosynthesis of chlorophyll and heme. Antineoplastic (photosensitizer) 
Usage : antineoplastic; topoisomerase I inhibitor 
Usage : A DNA topoisomerase I inhibitor; semisynthetic analog of Camptothecin. Antineoplastic. Topotecan hydrochloride is a chemotherapy agent that is a topoisomerase 1 inhibitor. 


Anticancer drug 

Topotecan hydrochloride is a water-soluble derivative of camptothecin, which is the form of hydrochloride of topotecan. It is successfully developed by the SmithKline Beecham US company, and approved by the FDA in the United States in 1996. Its trade name is Hycamtin. It is applied in the treatment of ovarian cancer (OVC) as the second-line therapy. 

In 1999 the US Food and Drug Administration (FDA) has approved topotecan hydrochloride as small cell lung cancer (SCLC) therapeutic drug. It has been available in the UK, Germany, France and other dozens of countries and regions. The 3 clinical trials are ongoing for this medicine which is used to treat non-small cell lung cancer, cervical cancer, myelodysplastic syndrome. 

Topotecan hydrochloride can enter the blood brain barrier. It has the same effect of oral and intravenous injection. The drug has low toxicity predictable bone marrow suppression, and other minor non-hematologic toxicity. Currently there are manufacturers, for clinical treatment of small cell lung cancer, ovarian cancer and other tumors.

Topotecan hydrochloride inhibits the activity of topoisomerase I, which is required for DNA replication. After intravenous injection, the product is hydrolyzed in the blood, and excreted by urinary. This product has a rapid serum clearance rate, which is 62L/h. It is widely distributed in vivo, and Its half-lifetime is about 2~3h. Preclinical trials have shown that the product has anti-tumor activity on all kinds of types of tumor. In I clinical trial, to patients with ovarian cancer that is cisplatin tolerance, this product also has significant anti-tumor effect. 


Topotecan hydrochloride Clinical studies 

In a open randomized trial, 226 cases who used cisplatin or carboplatin invalid or recurrent advanced ovarian cancer women changed to this product, and compared with paclitaxel. In 112 patients who used topotecan hydrochloride, 22 cases were effective, so the effective rate was 20%. In 114 patients treated with paclitaxel, 14 cases were effective, so the effective rate was 12%. Used this product for treatment which has made significant improvement in the average time of 23 weeks, while 14 weeks for paclitaxel. In a non-controlled trial to 111 women patients with refractory advanced ovarian cancer, 16 cases were preferabe after treatment, occupied with 14%, and the curative effect average time was 16-week, and the average survival time was 52-week. In an open trial, 67 cases were ineffective treated with cisplatin and paclitaxel for advanced ovarian cancer. However, 9 cases who changed to this product were effective, and the effective rate was 13%. 


Topotecan hydrochloride Side effects 

It can appear toxicity of bone marrow suppression in limited doses, especially it can cause neutropenia. It often induced thrombocytopenia and anemia. Sometimes red blood cell and platelet transfusion is necessary. It can also be nausea, vomiting, hair loss, diarrhea, abdominal pain, gastritis and weakness, but all of them were mild.  


Topotecan hydrochloride Uses 

It is used as antineoplastic agent. 


 
More products you may like

Sulbutiamine CAS 3286-46-2
Aniracetam CAS 72432-10-1
Noopept CAS 157115-85-0
Idra-21 CAS 22503-72-6
NSI-189 Free Base CAS 1270138-40-3
NSI-189 Phosphate CAS 1270138-41-4
9-fluorenol CAS 1689-64-1
Coluracetam CAS 135463-81-9
Sunifiram CAS 314728-85-3
Pramiracetam CAS 68497-62-1
4-Aminobutyric acid CAS 56-12-2
Piracetam CAS 7491-74-9
Oxiracetam CAS 62613-82-5
Fasoracetam CAS 110958-19-5
Nefiracetam CAS 77191-36-7
Centrophenoxine CAS 3685-84-5
Pikamilon Sodium CAS 62936-56-5
PRL-8-53 HCL CAS : 51352-87-5
Meclofenoxate hydrochloride CAS : 3685-84-5
Levodopa(L-DOPA) CAS : 59-92-7
Etiracetam(UCB-6474) CAS : 33996-58-6

Herbal Tea & Dry Flower Tea

Herbal Tea,Dry Flower Tea,Flower Tea

Runming Tea Co., Ltd. , http://www.onlinechinagreentea.com